TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism

A Astrid F. Feiten K Kilian Dahm K Kai Schlepckow B Bettina van Lengerich J Jung H. Suh A Anika Reifschneider B Benedikt Wefers L Laura M. Bartos K Karin Wind-Mark L Lis de Weerd T Thomas Ulas E Elena De-Domenico P Pia Grundschöttel S Stefan Paulusch B Benjamin Tast T Tamisa Honda S Stephan A. Müller M Matthias Becker I Igor Khalin A Alessio Ricci A Arthur Liesz (Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität München) B Bettina Brunner C Claudia Krenner K Katrin Buschmann B Brigitte Nuscher L Lena Spieth N Niklas Junker S Stefan A. Berghoff S Sonnet S. Davis J Jonas J. Neher (Biomedical Center, Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München) W Wolfgang Wurst N Nikolaus Plesnila J Joseph W. Lewcock M Mikael Simons S Stefan F. Lichtenthaler G Gilbert Di Paolo M Matthias Brendel A Anja Capell K Kathryn M. Monroe J Joachim L. Schultze C Christian Haass

Abstract

Abstract Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer’s disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in microglia, we generated a TREM2 reporter mouse. In APP transgenic animals, bulk RNA-sequencing of isolated microglia sorted based on reporter expression highlighted TREM2 level-related changes in major immunometabolic pathways, and enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. Metabolic and lipidomic profiling of sorted microglia showed that, independent of Aβ pathology, TREM2 expression correlated with signatures consistent with increased cellular redox, energetics, and cholesterol homoeostasis. In accordance, metabolic activity correlated with phagocytic capacity. Finally, we performed chronic treatment with a TREM2 agonist antibody and identified a window of TREM2 expression where microglia are most responsive, thereby informing clinical applications of TREM2 agonists.

Article Details

Volume / Issue Vol. 17, Issue 1
Published January 24, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (41)

A

Astrid F. Feiten

K

Kilian Dahm

K

Kai Schlepckow

B

Bettina van Lengerich

J

Jung H. Suh

A

Anika Reifschneider

B

Benedikt Wefers

L

Laura M. Bartos

K

Karin Wind-Mark

L

Lis de Weerd

T

Thomas Ulas

E

Elena De-Domenico

P

Pia Grundschöttel

S

Stefan Paulusch

B

Benjamin Tast

T

Tamisa Honda

S

Stephan A. Müller

M

Matthias Becker

I

Igor Khalin

A

Alessio Ricci

A

Arthur Liesz

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität München

B

Bettina Brunner

C

Claudia Krenner

K

Katrin Buschmann

B

Brigitte Nuscher

L

Lena Spieth

N

Niklas Junker

S

Stefan A. Berghoff

S

Sonnet S. Davis

J

Jonas J. Neher

Biomedical Center, Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München

W

Wolfgang Wurst

N

Nikolaus Plesnila

J

Joseph W. Lewcock

M

Mikael Simons

S

Stefan F. Lichtenthaler

G

Gilbert Di Paolo

M

Matthias Brendel

A

Anja Capell

K

Kathryn M. Monroe

J

Joachim L. Schultze

C

Christian Haass